A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma

The Danish metastatic melanoma database (DAMMED): A nation-wide platform for quality assurance and research in real-world data on medical therapy in Danish melanoma patients

(2021) Eva Ellebaek et al.   Cancer Epidemiology

Efficacy of immune checkpoint inhibitors and age in cancer patients

(2020) Xuan-zhang Huang et al.   Immunotherapy

PD-L1 engagement on T cells promotes self-tolerance and suppression of neighboring macrophages and effector T cells in cancer

(2020) Brian Diskin et al.   NATURE IMMUNOLOGY

An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma

(2020) Ugur Sahin et al.   NATURE

Peptide vaccination directed against IDO1-expressing immune cells elicits CD8+ and CD4+ T-cell-mediated antitumor immunity and enhanced anti-PD1 responses

(2020) Souvik Dey et al.   Journal for ImmunoTherapy of Cancer

A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer

(2020) Patrick A. Ott et al.   CELL

Impact of Age on the Efficacy of Immune Checkpoint Inhibitor-Based Combination Therapy for Non-small-Cell Lung Cancer: A Systematic Review and Meta-Analysis

(2020) Xin Yan et al.   Frontiers in Oncology

Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study

(2019) Caroline Robert et al.   LANCET ONCOLOGY

Age favoured overall survival in a large population-based Danish patient cohort treated with anti-PD1 immune checkpoint inhibitor for metastatic melanoma

(2019) Lars Bastholt et al.   EUROPEAN JOURNAL OF CANCER

Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study

(2019) Georgina V Long et al.   LANCET ONCOLOGY

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

(2019) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Balance Players of the Adaptive Immune System

(2018) Mads Hald Andersen   CANCER RESEARCH

A cancer vaccine-mediated postoperative immunotherapy for recurrent and metastatic tumors

(2018) Tingting Wang et al.   Nature Communications

Warming “Cold” Melanoma with TLR9 Agonists

(2018)   Cancer Discovery

Combination of Ipilimumab and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma

(2018) John E. Mullinax et al.   Frontiers in Oncology

Anti-cancer immunotherapy: breakthroughs and future strategies

(2018) Mads Hald Andersen   Seminars in Immunopathology

Durable Clinical Responses and Long-Term Follow-Up of Stage III–IV Non-Small-Cell Lung Cancer (NSCLC) Patients Treated With IDO Peptide Vaccine in a Phase I Study—A Brief Research Report

(2018) Julie Westerlin Kjeldsen et al.   Frontiers in Immunology

Real-world Data for Clinical Evidence Generation in Oncology

(2017) Sean Khozin et al.   JNCI-Journal of the National Cancer Institute

An immunogenic personal neoantigen vaccine for patients with melanoma

(2017) Patrick A. Ott et al.   NATURE

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

(2017) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Real-world Data for Clinical Evidence Generation in Oncology

(2017) Sean Khozin et al.   JNCI-Journal of the National Cancer Institute

PD-L1-specific T cells

(2016) Shamaila Munir Ahmad et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen

(2016) R. Andersen et al.   CLINICAL CANCER RESEARCH

Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents

(2016) Jeffrey S. Weber et al.   ONCOLOGIST

PD-L1 peptide co-stimulation increases immunogenicity of a dendritic cell-based cancer vaccine

(2016) Shamaila Munir Ahmad et al.   OncoImmunology

Dynamics of the Cytotoxic T Cell Response to a Model of Acute Viral Infection

(2015) William S. DeWitt et al.   JOURNAL OF VIROLOGY

Nivolumab in Previously Untreated Melanoma without BRAF Mutation

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

HIV-1-Specific T Cell Precursors with High Proliferative Capacity Correlate with Low Viremia and High CD4 Counts in Untreated Individuals

(2014) Sandra A. Calarota et al.   JOURNAL OF IMMUNOLOGY

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

The stimulation of PD-L1-specific cytotoxic T lymphocytes can both directly and indirectly enhance antileukemic immunity

(2014) S M Ahmad et al.   Blood Cancer Journal

HLA-Restricted CTL That Are Specific for the Immune Checkpoint Ligand PD-L1 Occur with High Frequency in Cancer Patients

(2013) S. Munir et al.   CANCER RESEARCH

Long-lasting Disease Stabilization in the Absence of Toxicity in Metastatic Lung Cancer Patients Vaccinated with an Epitope Derived from Indoleamine 2,3 Dioxygenase

(2013) T. Z. Iversen et al.   CLINICAL CANCER RESEARCH

Harnessing PD-L1-specific cytotoxic T cells for anti-leukemia immunotherapy to defeat mechanisms of immune escape mediated by the PD-1 pathway

(2013) S M Ahmad et al.   LEUKEMIA

Using synthetic templates to design an unbiased multiplex PCR assay

(2013) Christopher S. Carlson et al.   Nature Communications

The immune checkpoint regulator PD-L1 is a specific target for naturally occurring CD4+T cells

(2013) Shamaila Munir et al.   OncoImmunology

The specific targeting of immune regulation: T-cell responses against Indoleamine 2,3-dioxygenase

(2012) Mads Hald Andersen   CANCER IMMUNOLOGY IMMUNOTHERAPY

Natural CD4+ T-Cell Responses against Indoleamine 2,3-Dioxygenase

(2012) Shamaila Munir et al.   PLoS One

CD4 responses against IDO

(2012) Mads Hald Andersen   OncoImmunology

Spontaneous Cytotoxic T-Cell Reactivity against Indoleamine 2,3-Dioxygenase-2

(2011) R. B. Sorensen et al.   CANCER RESEARCH

Ultra-sensitive detection of rare T cell clones

(2011) Harlan Robins et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Characterization and Comparison of ‘Standard’ and ‘Young’ Tumour-Infiltrating Lymphocytes for Adoptive Cell Therapy at a Danish Translational Research Institution

(2011) M. Donia et al.   SCANDINAVIAN JOURNAL OF IMMUNOLOGY

siRNA silencing of PD-L1 and PD-L2 on dendritic cells augments expansion and function of minor histocompatibility antigen-specific CD8+ T cells

(2010) W. Hobo et al.   BLOOD

Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators

(2010) R. B. Sorensen et al.   BLOOD

High immunogenic potential of p53 mRNA-transfected dendritic cells in patients with primary breast cancer

(2010) Özcan Met et al.   BREAST CANCER RESEARCH AND TREATMENT

Response definition criteria for ELISPOT assays revisited

(2010) Z. Moodie et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

A simple forward selection procedure based on false discovery rate control

(2009) Yoav Benjamini et al.   Annals of Applied Statistics

Comprehensive assessment of T-cell receptor  -chain diversity in    T cells

(2009) H. S. Robins et al.   BLOOD

The Immune System Strikes Back: Cellular Immune Responses against Indoleamine 2,3-dioxygenase

(2009) Rikke Bæk Sørensen et al.   PLoS One